247 related articles for article (PubMed ID: 16527881)
1. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).
Deighton CM; George E; Kiely PD; Ledingham J; Luqmani RA; Scott DG
Rheumatology (Oxford); 2006 Jun; 45(6):649-52. PubMed ID: 16527881
[No Abstract] [Full Text] [Related]
2. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
Ledingham J; Deighton C;
Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
[No Abstract] [Full Text] [Related]
3. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
Haraoui B
J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
[No Abstract] [Full Text] [Related]
4. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
[TBL] [Abstract][Full Text] [Related]
5. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2008; 55(1):22-5. PubMed ID: 19024266
[TBL] [Abstract][Full Text] [Related]
6. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
Ding T; Ledingham J; Luqmani R; Westlake S; Hyrich K; Lunt M; Kiely P; Bukhari M; Abernethy R; Bosworth A; Ostor A; Gadsby K; McKenna F; Finney D; Dixey J; Deighton C; ;
Rheumatology (Oxford); 2010 Nov; 49(11):2217-9. PubMed ID: 20837498
[No Abstract] [Full Text] [Related]
7. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
8. [Statement of the German Society of Rheumatology (DGRh) reporting on the Institute's plan for biologicals in the second-line therapy for rheumatoid arthritis].
Braun J; Krüger K; Genth E
Z Rheumatol; 2011 Dec; 70(10):882-3. PubMed ID: 22139207
[No Abstract] [Full Text] [Related]
9. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
Emery P; Van Vollenhoven R; Ostergaard M; Choy E; Combe B; Graninger W; Krueger K; Matucci-Cerinic M; Navarro F; van Riel P; Settas L; Steinfeld S
Ann Rheum Dis; 2009 Apr; 68(4):456-9. PubMed ID: 19286904
[No Abstract] [Full Text] [Related]
10. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
[TBL] [Abstract][Full Text] [Related]
11. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
Kay LJ; Griffiths ID;
Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
[TBL] [Abstract][Full Text] [Related]
12. [Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].
Z Rheumatol; 2000 Aug; 59(4):291-2. PubMed ID: 11013988
[No Abstract] [Full Text] [Related]
13. Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement.
Deighton C; Hyrich K
Rheumatology (Oxford); 2008 Nov; 47(11):1600-2. PubMed ID: 18784124
[No Abstract] [Full Text] [Related]
14. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.
Fautrel B; Pham T; Mouterde G; Le Loët X; Goupille P; Guillemin F; Ravaud P; Cantagrel A; Dougados M; Puéchal X; Sibilia J; Soubrier M; Mariette X; Combe B; ;
Joint Bone Spine; 2007 Dec; 74(6):627-37. PubMed ID: 18037319
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
16. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
Marshall NJ; Wilson G; Lapworth K; Kay LJ
Rheumatology (Oxford); 2004 Aug; 43(8):1034-8. PubMed ID: 15150436
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
[No Abstract] [Full Text] [Related]
18. Guidance for practitioners on the assessment, administration and monitoring of biologic therapies for inflammatory arthritis.
Oliver S
Musculoskeletal Care; 2003 Sep; 1(2):135-40. PubMed ID: 20217674
[No Abstract] [Full Text] [Related]
19. An error in the revised anti-TNF therapy guidelines for adult RA.
Deighton C; Ledingham J
Rheumatology (Oxford); 2006 Sep; 45(9):1170. PubMed ID: 16769774
[No Abstract] [Full Text] [Related]
20. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
Deighton C; Hyrich K; Ding T; Ledingham J; Lunt M; Luqmani R; Kiely P; Bukhari M; Abernethy R; Ostor A; Bosworth A; Gadsby K; McKenna F; Finney D; Dixey J;
Rheumatology (Oxford); 2010 Jun; 49(6):1197-9. PubMed ID: 20308121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
